Form 4: Fairmount Funds Management LLC Reports Pro Rata Distribution of Dianthus Therapeutics Shares

Fairmount Funds Management LLC reports a pro rata distribution of 62,146 common stock shares of Dianthus Therapeutics, Inc. to its membership interest investors on September 27, 2024.

Summary

• Fairmount Funds Management LLC filed a Form 4 on October 1, 2024, reporting changes in beneficial ownership of Dianthus Therapeutics, Inc. (DNTH) common stock.
• The transaction involved a pro rata distribution of 62,146 shares of common stock by Fairmount SPV III, LLC to its membership interest investors on September 27, 2024, at a price of $0.00.
• Fairmount Healthcare Fund II L.P. is also listed as indirectly owning 2,700,691 shares of Dianthus Therapeutics, Inc. common stock.
• Tomas Kiselak, as Managing Member of Fairmount Funds Management LLC, signed the report, disclaiming beneficial ownership except to the extent of pecuniary interest.
• Fairmount, Fund II and Fairmount SPV III, LLC may each be deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is a Managing Member of Fairmount.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, indicating a neutral sentiment.

Management Comments

• Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Industry Context

Form 4 filings are standard disclosures required by the SEC for insiders of publicly traded companies, providing transparency into their transactions and holdings.

Stakeholder Impact

• The pro rata distribution may have a minor impact on shareholders, depending on the size and distribution of shares.

Key Dates